Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by CENTRAL TRUST Co

CENTRAL TRUST Co grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,466 shares of the biopharmaceutical company’s stock after purchasing an additional 1,021 shares during the period. CENTRAL TRUST Co’s holdings in Regeneron Pharmaceuticals were worth $1,757,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Clearbridge Investments LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $1,506,000. Centaurus Financial Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $118,000. Czech National Bank boosted its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after purchasing an additional 1,405 shares during the period. Park Avenue Securities LLC grew its position in Regeneron Pharmaceuticals by 7.6% during the third quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company’s stock valued at $1,986,000 after purchasing an additional 134 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Regeneron Pharmaceuticals by 32.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,436 shares of the biopharmaceutical company’s stock valued at $1,510,000 after buying an additional 353 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $672.98 on Monday. The firm has a fifty day moving average price of $720.81 and a two-hundred day moving average price of $922.87. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $73.95 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on REGN shares. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Oppenheimer dropped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.